Back to trial detailsIntake questionnaire
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Applying to Rush University Medical Center · Chicago, Illinois
Answer a few short questions to share with the research team.
0 of 4 answered